ARTICLE | Company News

Bavarian Nordic, J&J deal

October 27, 2014 7:00 AM UTC

Bavarian Nordic granted the Johnson & Johnson's Crucell Holland B.V. exclusive, worldwide rights to Ebola vaccine MVA-BN Filo. Bavarian Nordic will receive an upfront payment of $25 million and is eligible to up to $20 million in development and regulatory milestones, plus royalties for commercial sales outside Africa. Concurrently, Johnson & Johnson Development Corp. will acquire a 6.4% stake in Bavarian Nordic for DKK251 million ($43 million) via a private placement of new shares. Crucell will be responsible for costs associated with the development and commercialization of the third-generation modified vaccinia Ankara (MVA) multivalent vaccine for the Zaire and Sudan strains of Ebola as well as Marburg virus.

Bavarian Nordic said Janssen will pay it $99.3 million for more than 1 million doses of the vaccine, via a $70.8 million upfront payment and $28.5 million to be paid pro rata upon delivery next year. It anticipates that at least 250,000 doses will be ready for use in clinical trials by May 2015. ...